Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
Turner NC, Reis-Filho JS. Tackling the diversity of triple-negative breast cancer. Clin Cancer Res. 2013;19:6380–8.
Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake 2nd DD, et al. Somatic mutations in brca1 and brca2 could expand the number of patients that benefit from poly (adp ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28:3570–6.
Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of brca mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17:1082–9.
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene brca1. Science. 1994;266:66–71.
Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-negative breast cancer. Cancer Res. 2013;73:2025–30.
Wong-Brown MW, Meldrum CJ, Carpenter JE, Clarke CL, Narod SA, Jakubowska A, et al. Prevalence of brca1 and brca2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150:71–80.
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene brca2. Nature. 1995;378:789–92.
Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell. 1999;4:511–8.
Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, Livingston DM. Genetic analysis of brca1 function in a defined tumor cell line. Mol Cell. 1999;4:1093–9.
McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(adp-ribose) polymerase inhibition. Cancer Res. 2006;66:8109–15.
Neuhausen SL, Brummel S, Ding YC, Singer CF, Pfeiler G, Lynch HT, et al. Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among brca1 and brca2 carriers. Breast Cancer Res. 2009;11:R76.
Hudelist G, Wagner T, Rosner M, Fink-Retter A, Gschwantler-Kaulich D, Czerwenka K, et al. Intratumoral igf-i protein expression is selectively upregulated in breast cancer patients with brca1/2 mutations. Endocr Relat Cancer. 2007;14:1053–62.
Maor S, Yosepovich A, Papa MZ, Yarden RI, Mayer D, Friedman E, et al. Elevated insulin-like growth factor-i receptor (igf-ir) levels in primary breast tumors associated with brca1 mutations. Cancer Lett. 2007;257:236–43.
Pasanisi P, Bruno E, Venturelli E, Manoukian S, Barile M, Peissel B, et al. Serum levels of igf-i and brca penetrance: A case control study in breast cancer families. Fam Cancer. 2011;10:521–8.
Beck EP, Russo P, Gliozzo B, Jaeger W, Papa V, Wildt L, et al. Identification of insulin and insulin-like growth factor i (igf i) receptors in ovarian cancer tissue. Gynecol Oncol. 1994;53:196–201.
Brokaw J, Katsaros D, Wiley A, Lu L, Su D, Sochirca O, et al. Igf-i in epithelial ovarian cancer and its role in disease progression. Growth Factors. 2007;25:346–54.
Karasik A, Menczer J, Pariente C, Kanety H. Insulin-like growth factor-i (igf-i) and igf-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab. 1994;78:271–6.
Weigang B, Nap M, Bittl A, Jaeger W. Immunohistochemical localization of insulin-like growth factor 1 receptors in benign and malignant tissues of the female genital tract. Tumour Biol. 1994;15:236–46.
Yee D, Morales FR, Hamilton TC, Von Hoff DD. Expression of insulin-like growth factor i, its binding proteins, and its receptor in ovarian cancer. Cancer Res. 1991;51:5107–12.
Christopoulos PF, Msaouel P, Koutsilieris M. The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer. 2015;14:43.
Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, et al. Insulin-like growth factor receptor i targeting in epithelial ovarian cancer. Gynecol Oncol. 2006;100:389–96.
Resnicoff M, Ambrose D, Coppola D, Rubin R. Insulin-like growth factor-1 and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Lab Invest. 1993;69:756–60.
Beauchamp MC, Knafo A, Yasmeen A, Carboni JM, Gottardis MM, Pollak MN, et al. Bms-536924 sensitizes human epithelial ovarian cancer cells to the parp inhibitor, 3-aminobenzamide. Gynecol Oncol. 2009;115:193–8.
Beauchamp MC, Yasmeen A, Knafo A, Gotlieb WH. Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol. 2010;2010:257058.
An Y, Cai Y, Guan Y, Cai L, Yang Y, Feng X, et al. Inhibitory effect of small interfering rna targeting insulin-like growth factor-i receptor in ovarian cancer ovcar3 cells. Cancer Biother Radiopharm. 2010;25:545–52.
27 Hartog H, Boezen HM, de Jong MM, Schaapveld M, Wesseling J, van der Graaf WT. Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer. Breast (Edinburgh, Scotland) 2013;22:1155–1160.
28 Davison Z, de Blacquiere GE, Westley BR, May FE. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: Implications for therapy. Neoplasia (New York, NY) 2011;13:504–515.
Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D. The type i insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene. 2010;29:251–62.
Saldana SM, Lee HH, Lowery FJ, Khotskaya YB, Xia W, Zhang C, et al. Inhibition of type i insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis. PLoS ONE. 2013;8:e73406.
Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D, Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene. 2010;29:2517–27.
Chitnis MM, Lodhia KA, Aleksic T, Gao S, Protheroe AS, Macaulay VM. Igf-1r inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination. Oncogene. 2013.
Cosaceanu D, Carapancea M, Castro J, Ekedahl J, Kanter L, Lewensohn R, et al. Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. Cancer Lett. 2005;222:173–81.
Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, et al. Brca1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res. 2006;66:41–5.
Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, et al. Brca1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious brca1 mutation. Mol Oncol. 2013;7:567–79.
Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, et al. Pi3k inhibition impairs brca1/2 expression and sensitizes brca-proficient triple-negative breast cancer to parp inhibition. Cancer Discovery. 2012;2:1036–47.
Maor S, Papa MZ, Yarden RI, Friedman E, Lerenthal Y, Lee SW, et al. Insulin-like growth factor-i controls brca1 gene expression through activation of transcription factor sp1. Horm Metab Res. 2007;39:179–85.
Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315–9.
Chou TC. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res. 2010;70:440–6.
RL OD, McCormick A, Mukhopadhyay A, Woodhouse LC, Moat M, Grundy A, et al. The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis. PLoS ONE. 2014;9:e90604.
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(adp-ribose) polymerase in tumors from brca mutation carriers. N Engl J Med. 2009;361:123–34.
Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in brca1-mutation carriers. Breast cancer linkage consortium. Am J Hum Genet. 1995;56:265–71.
Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of brca1 and brca2 among ashkenazi jews. N Engl J Med. 1997;336:1401–8.
Chen S, Parmigiani G. Meta-analysis of brca1 and brca2 penetrance. J Clin Oncol. 2007;25:1329–33.
Abramovitch S, Glaser T, Ouchi T, Werner H. Brca1-sp1 interactions in transcriptional regulation of the igf-ir gene. FEBS Lett. 2003;541:149–54.
Amichay K, Kidron D, Attias-Geva Z, Schayek H, Sarfstein R, Fishman A, et al. Brca1 is expressed in uterine serous carcinoma (usc) and controls insulin-like growth factor i receptor (igf-ir) gene expression in usc cell lines. Int J Gynecol Cancer. 2012;22:748–54.
Attias-Geva Z, Bentov I, Kidron D, Amichay K, Sarfstein R, Fishman A, et al. P53 regulates insulin-like growth factor-i receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-i receptor-directed targeted therapy. Eur J Cancer. 2012;48:1570–80.
Shukla V, Coumoul X, Cao L, Wang RH, Xiao C, Xu X, et al. Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members. Cancer Res. 2006;66:7151–7.
Lodhia KA, Gao S, Aleksic T, Esashi F, Macaulay VM. Suppression of homologous recombination sensitizes human tumor cells to igf-1r inhibition. Int J Cancer. 2015;136(12):2961–6. doi:10.1002/ijc.29327.
Chen HX, Sharon E. Igf-1r as an anti-cancer target--trials and tribulations. Chin J Cancer. 2013;32:242–52.
Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, et al. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (cp-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol. 2009;4:1397–403.
Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P. Meijers M, et al. Clin Cancer Res: Functional ex vivo assay to select homologous recombination deficient breast tumors for parp inhibitor treatment; 2014.
Trojanek J, Ho T, Del Valle L, Nowicki M, Wang JY, Lassak A, et al. Role of the insulin-like growth factor i/insulin receptor substrate 1 axis in rad51 trafficking and DNA repair by homologous recombination. Mol Cell Biol. 2003;23:7510–24.
Wang Y, Yuan JL, Zhang YT, Ma JJ, Xu P, Shi CH, et al. Inhibition of both egfr and igf1r sensitized prostate cancer cells to radiation by synergistic suppression of DNA homologous recombination repair. PLoS ONE. 2013;8:e68784.
Turney BW, Kerr M, Chitnis MM, Lodhia K, Wang Y, Riedemann J, et al. Depletion of the type 1 igf receptor delays repair of radiation-induced DNA double strand breaks. Radiother Oncol. 2012;103:402–9.